glp-1 long term safety receptor agonism: a transformative approach for managing type-2 diabetes and obesity | Saudi Pharmaceutical Journal As GLP-1 Use Expands, Long-Term

What are the bad side effects of Semaglutide

Ignoring metabolic markers Weight is one data point

In general, without knowing what Medicaid and Medicare generally are currently paying for these drugs on net, it is uncertain whether the lower prices that will be made available to state Medicaid programs and Part D plans under the BALANCE Model for currently covered uses of GLP-1s will generate enough savings to offset the additional costs from expanded use of these medications for obesity

All three speak to each other, and for that, parts of the brain play a role, explains Giles Yeo, a University of Cambridge professor who specializes in the genetics of body weight and the neuroscience of food intake